Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 13/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420274 | 1.00 | KMT2A (0.45) | KMT2AGRIA4GRIA2UBE2NLMNA | |
| SCHEMBL15420276 | 1.00 | KMT2A (0.45) | KMT2AGRIA4GRIA2UBE2NLMNA | |
| SCHEMBL15420749 | 0.88 | KMT2A (0.45) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL12987874 | 0.88 | KMT2A (0.45) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL15440843 | 0.88 | KMT2A (0.45) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL15420346 | 0.88 | KMT2A (0.45) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL12987876 | 0.88 | KMT2A (0.45) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL12987970 | 0.87 | GRIA4 (0.48) | GRIA4GRIA2 | |
| SCHEMBL12987035 | 0.87 | KMT2A (0.44) | KMT2AUBE2NLMNAALDH1A1GAA | |
| SCHEMBL15440976 | 0.87 | GRIA4 (0.48) | GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | KMT2A 542/4885GRIA4 6/4885GRIA2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.